LIVE AND IN-VIVO TUMOR SPECIFIC CANCER VACCINE SYSTEM DEVELOPED BY CO-ADMINISTRATION OF EITHER AT LEAST TWO OR ALL THREE OF THE FOLLOWING COMPONENTS SUCH AS TUMOR CELLS, AN ONCOLYTIC VIRUS VECTOR WITH TRANSGENIC EXPRESSION OF GM-CSF AND AN IMMUNE CHECKPOINT MODULATOR

• US 20150190505A1
• Filed: 07/22/2013
• Published: 07/09/2015
• Est. Priority Date: 07/30/2012
• Status: Abandoned Application

• Current Assignee: CG Oncology, Inc.
• Original Assignee: CG Oncology, Inc.
• Inventors: Yeung, Alex Wah Hin
• Application Number:
  US14/409,383
• Publication Number:
  US 20150190505A1
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 35/761 Adenovirus
• CPC Class Codes: A61K 39/235 Adenoviridae
• CPC Class Codes: A61K 39/39558 against tumor tissues, cells, antigens
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C07K 16/2818 against CD28 or CD152
• CPC Class Codes: C07K 2317/75 Agonist effect on antigen
• CPC Class Codes: C12N 2710/10332 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Abstract

The invention discloses a novel tumor-specific complete vaccine system generated in-vivo. This vaccine system is developed by the use of separated tumor cells inactivated by irradiation and the in-vivo interaction with an oncolytic viral vector with transgenic expression of GM-CSF, completed with immune checkpoint modulators (“ICM”) such as co-stimulatory signals confirmation with an anti-CTLA4 antibody. Specifically there will be no pre-incubation or interaction of the either two or all three components before administration to the patient. One of such oncolytic viral vector examples is CG0070 (GM-CSF expressing conditionally replication competent adenovirus). Mixing of the tumor-viral-ICM components will take place just prior to administration to preserve the effects of the oncolytic process and subsequent immunotherapeutic responses to be live and in vivo from the very first beginning. This invention is a complete live and in-vivo cancer vaccine system (“CLIVS”).

Claims

1. A tumor-specific immunotherapeutic vaccine system which is an apparatus comprising:

at least two of the three components of;

a. separated tumor cells isolated and inactivated by irradiation,

b. an oncolytic viral and a cancer specific vector comprising a heterologous nucleic acid encoding GM-CSF and

c. an immune checkpoint modulator (“

ICM”

),

wherein the two or three components are admixed just prior to administration to patient without any pre-incubation.

2. The tumor-specific immunotherapeutic vaccine system of claim 1, wherein the immune checkpoint modulator is omitted.

3. The tumor-specific immunotherapeutic vaccine system of claim 1, wherein the immune checkpoint modulator is an anti-CTLA4 antibody.

4. The tumor-specific immunotherapeutic vaccine system of claim 1, wherein the anti-CTLA4 antibody is selected from ipilimumab, tremilimuab and a single chain anti-CTLA-4 antibody.

5. The tumor-specific immunotherapeutic vaccine system of claim 1, wherein the immune checkpoint modulator is an OX40 binding agent or agonist, or an OX40L molecule.

6. The tumor-specific immunotherapeutic vaccine system of claim 1, wherein the immune checkpoint modulator is an antibody or modulator selected from a group of molecules or antibodies targeted against or modulate PD1, TIM3, B7-H3, B7-H4, LAG-3 and KIR, or its ligands.

7. The tumor-specific immunotherapeutic vaccine system of claim 1, wherein the immune checkpoint modulator is a combination of two or more of an anti-CTLA4 antibody selected from the group of:

an anti-CTLA4 antibody;

ipilimumab, tremilimuab and a single chain anti-CTLA-4 antibody;

an OX40 binding agent or agonist, or an OX40L molecule;

or a group of molecules or antibodies targeted against or modulate PD1, TIM3, B7-H3, B7-H4, LAG-3 and KIR, or its ligands.

8. The tumor-specific immunotherapeutic vaccine system of claim 1, wherein the oncolytic and cancer specific viral vector expressing GM-CSF is from an adenovirus, such as CG0070.

9. The tumor-specific immunotherapeutic vaccine system of claim 1, wherein the oncolytic and cancer specific viral vector expressing GM-CSF is selected from viruses other than adenovirus, such as Herpes Simplex, Vaccinia, Mumps, Newcastle Disease and Reo viruses.

10. The tumor-specific immunotherapeutic vaccine system of claim 1, further comprising a kit comprising either at least two of three of the following components:

a. separated tumor cells isolated and inactivated by irradiation,

b. an oncolytic viral and a cancer specific vector comprising a heterologous nucleic acid encoding GM-CSF and

c. an immune checkpoint modulator (“

ICM”

), and a packaging insert containing directions for use.

11. The tumor-specific immunotherapeutic vaccine system of claim 1, further comprising a tumor cell preparation kit comprising:

materials and methods to conduct tumor dissociation and preparation, enzymatic and/or virus vector transduction agents, cryopreservation vials etc. and a packaging insert containing directions for use.

12. The tumor-specific immunotherapeutic vaccine system of claim 1, further comprising inducing a local and/or systemic specific immune response for cancer treatment, comprising administering to the patient the tumor specific immunotherapeutic vaccine system.

13. The tumor-specific immunotherapeutic vaccine system of claim 12, further comprising, whereby the source of the cancer cells is autologous.

14. The tumor-specific immunotherapeutic vaccine system of claim 12, further comprising, whereby the source of the cancer cells is allogeneic.

15. The tumor-specific immunotherapeutic vaccine system of claim 12, further comprising, whereby the source of the cancer cells is from cell culture systems.

16. The tumor-specific immunotherapeutic vaccine system of claim 12, further comprising, whereby the cancer cells are modified to secrete or express agents or receptors that may be beneficial for viral transduction and/or immune modulation, including but not limited to, an example such as GVAX, which are modified autologous or allogeneic cancer cells secreting GM-CSF.

17. The tumor-specific immunotherapeutic vaccine system of claim 12, further comprising, whereby the source of the cancer cells can be a combination of two or more cancer cell origins as specified in claims 13 to 16.

18. The tumor-specific immunotherapeutic vaccine system of claim 12, further comprising The method of claim 12, wherein the tumor-specific immunotherapeutic vaccine system is administered to the patient subcutaneously.

19. (canceled)

20. (canceled)

21. (canceled)

22. (canceled)

23. (canceled)

24. (canceled)

25. (canceled)

26. (canceled)

27. (canceled)

28. (canceled)